真实世界中注射用丹参多酚酸盐治疗冠心病的联合用药分析_常艳鹏

121*2231.1007002.1008723.100048。18。160550.759%。、。2013-05-08“”2009ZX09502-0307Z0255ZZ070817*[e-mail]、[e-mail]1。2、34。ＲWS14-5、6、7、HIS8-9。18HIS。11.118HIS1605。1.210。1.3①②IDID③IDID。1.4SPSS18.0SAS9.2Excel2007。clementine12.0Apriori。22.1、、。·6813·381820139Vol.38Issue18September201350.76%50.51%49.56%1。1Table1Injectionsalvianolateclinicalcommoncombination/%+50.759+50.506+49.558+44.437+38.875+37.8+37.295+36.789+36.726+35.588100%1.2.212。、、、。1Fig.1Injectionsalvianolatecombinedwithotherdrugsassoci-atedmap2.312、1058547。2.46166.52。WilcoxonP＜0.0001。2Table2Thehighestfrequencycombinationregimenswithotherprogramspatientage/95%95%10588660.93±10.3061.0060.2861.585476365.32±12.6366.5064.2066.452.53。3Table3Thehighestfrequencycombinationregimensinpa-tientswithotherprogramsgendercomparison/%/%66268.1125664.4831031.8914135.52861502.627.79%21.57%P＜0.0011605、4。4Table4Thehighestfrequencycombinationregimensconditionofhospitalizedpatientswithotherprograms/%/%29427.7911821.5776472.2142978.432.7·7813·381820139Vol.38Issue18September2013WilcoxonP＜0.00015。5Table5Thehighestfrequencycombinationregimenswithotherprogrampatientssingle-usethesalvianolateinjectiondose/mL95%95%1058196.74±20.03195.98197.50547290.29±253.47277.38303.200200。2.81.00dWilcoxon6。6Table6Frequencyhighestcombinedregimencomparisonwiththetreatmentofpatientswithotherprograms/d95%95%105802.75±3.112.632.87547372.68±3.242.522.851。2.97。7Table7Thehighestfrequencyregimentreatmentresultswithotherprograms/%/%274.71154.1254194.4234193.6830.5220.5520.3561.654851833、、、11-12HIS1605“”、、。50.76%50.51%49.56%。、1058。、13。、12。HIS·8813·381820139Vol.38Issue18September2013。。1.J.2010213324.2GartlehnerGHansenＲANissmanDetal.Asimpleandval-idtooldistinguishedefficacyfromeffectivenessstudiesJ.JClinEpidemiol2006591040.3KraemerHC.ＲulesofevidenceinassessingtheefficacyandeffectivenessoftreatmentsJ.DevNeuropsychol200324705.4.J.201084301.5．、GCPJ．201237192681．6.J.2013334437.7．J．2013546451．8.HIS“”J.201136202880.9.HISJ.201237182723.10.HISJ.201237172723.11.J.20049111209.12.J.2006172140.13.J.200313211.AnalysisofsalvianolateinjectioncombinedwithusualdrugsintreatmentofcoronaryheartdiseaseinrealworldCHANGYan-peng1ZHANGHui2XIEYan-ming1*ZENGXian-bin2HUJian2ZHUANGYan31．InstituteofＲesearchinClinicalMedicineChinaAcademyofChineseMedicalSciencesBeijing100700China2．ＲenminUniversityofChinaBeijing100872China3．ThePLANavyGeneralHospitalBeijing100048ChinaAbstractObjectiveBasedonrealworldresearchthecircumstancesoftheclinicaluseofusualdrugscombinedwithsalvi-anolateinjectionaresurveyed．MethodDescriptivestatisticsontheuseofsalvianolateinjectionin18generalhospitalsinChina．Ｒe-sultIn1605patientswithcoronaryheartdiseaseCHDsalvianolateinjectionwasmostfrequently51%combinedwithclopi-dogrelandisosorbidedinitrate．Inadditionthiscombinationshowedahigherclinicaleffectivenessascomparedwithotherdrugcombi-nations．ConclusionIntherealworldsalvianolateinjectioncombinedwithusualtreatmentwasfoundtobemoreeffectivethanothertreatmentcombinations．InadditionpracticeconformedtotheclinicaltreatmentofcoronaryheartdiseaseCHDguidelinesfordruguse．Howeverliverandkidneyfunctionroutinebloodtestsandtheblood'scoagulationfunctionrequireongoingmonitoring．Keywordssalvianolateinjectionrealworlddrugcombinationdoi10．4268/cjcmm20131846·9813·381820139Vol.38Issue18September2013